This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy ACP-196 and ACP 319 in B-cell malignancies.
SparkCures ID | 700 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 126 Patients |
Treatments |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Main Inclusion Criteria:
Exclusion Criteria
Please visit the ClinicalTrials.gov page for historical site information.
View Centers